NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $131.20
  • Forecasted Upside: 12.12 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$117.02
▼ -1.61 (-1.36%)
1 month | 3 months | 12 months
Get New Ultragenyx Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RARE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RARE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$131.20
▲ +12.12% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $131.20, with a high forecast of $186.00 and a low forecast of $66.00. The average price target represents a 12.12% upside from the last price of $117.02.
Buy
The current consensus among 14 investment analysts is to buy stock in Ultragenyx Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/12/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/11/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/10/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/8/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/6/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
12/5/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021Stifel NicolausInitiated CoverageBuy$179.00High
i
2/16/2021SVB LeerinkBoost Price TargetOutperform$115.00 ➝ $178.00Low
i
2/12/2021WedbushBoost Price TargetNeutral$113.00 ➝ $130.00Low
i
Rating by L. Chico at Wedbush
2/12/2021Piper SandlerBoost Price TargetOverweight$165.00 ➝ $170.00Low
i
2/12/2021BarclaysBoost Price TargetOverweight$176.00 ➝ $186.00Low
i
2/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$165.00Low
i
1/25/2021Credit Suisse GroupBoost Price TargetNeutral$64.00 ➝ $99.00High
i
1/11/2021Robert W. BairdBoost Price TargetOutperform$110.00 ➝ $165.00Medium
i
1/11/2021BarclaysBoost Price TargetOverweight$121.00 ➝ $176.00High
i
12/7/2020WedbushDowngradeOutperform ➝ Neutral$105.00 ➝ $110.00Medium
i
Rating by L. Chico at Wedbush
11/24/2020Evercore ISIReiterated RatingIn-Line$110.00High
i
11/12/2020Bank of AmericaDowngradeBuy ➝ Neutral$104.00 ➝ $126.00High
i
10/29/2020Canaccord GenuityBoost Price TargetBuy$92.00 ➝ $105.00High
i
10/28/2020TruistBoost Price Target$88.00 ➝ $110.00High
i
10/28/2020WedbushBoost Price TargetOutperform$97.00 ➝ $105.00Low
i
10/28/2020Morgan StanleyBoost Price TargetOverweight$89.00 ➝ $91.00Low
i
10/28/2020BarclaysBoost Price TargetOverweight$99.00 ➝ $121.00Medium
i
10/28/2020SVB LeerinkBoost Price TargetOutperform$110.00 ➝ $115.00Medium
i
10/27/2020Piper SandlerBoost Price TargetOverweight$83.00 ➝ $108.00Medium
i
10/15/2020Bank of AmericaBoost Price TargetBuy$93.00 ➝ $107.00Medium
i
10/13/2020Morgan StanleyBoost Price TargetOverweight$87.00 ➝ $89.00Medium
i
8/26/2020Canaccord GenuityBoost Price TargetBuy$91.00 ➝ $92.00High
i
7/31/2020Credit Suisse GroupReiterated RatingHold$64.00Low
i
Rating by Martin Auster at Credit Suisse Group AG
7/31/2020Morgan StanleyLower Price TargetOverweight$88.00 ➝ $87.00High
i
7/31/2020BarclaysBoost Price TargetOverweight$87.00 ➝ $99.00Low
i
7/28/2020JPMorgan Chase & Co.Reiterated RatingBuy$84.00High
i
7/15/2020Morgan StanleyBoost Price TargetOverweight$83.00 ➝ $88.00Low
i
7/2/2020Canaccord GenuityBoost Price TargetBuy$85.00 ➝ $91.00Medium
i
7/1/2020SunTrust BanksBoost Price Target$82.00 ➝ $88.00Medium
i
Rating by Joon Lee at SunTrust Banks, Inc.
7/1/2020Credit Suisse GroupBoost Price TargetNeutral$60.00 ➝ $64.00High
i
7/1/2020JPMorgan Chase & Co.Boost Price TargetOverweight$76.00 ➝ $84.00High
i
7/1/2020WedbushBoost Price TargetHold ➝ Outperform$83.00 ➝ $91.00High
i
7/1/2020Morgan StanleyBoost Price TargetOverweight$79.00 ➝ $83.00High
i
7/1/2020Robert W. BairdBoost Price TargetOutperform$75.00 ➝ $90.00High
i
Rating by Michael Ulz at Robert W. Baird
6/30/2020Piper SandlerBoost Price TargetOverweight$70.00 ➝ $83.00High
i
6/19/2020SunTrust BanksBoost Price TargetBuy$80.00 ➝ $82.00High
i
Rating by Joon Lee at SunTrust Banks, Inc.
6/19/2020WedbushBoost Price TargetOutperform$73.00 ➝ $83.00High
i
6/19/2020Canaccord GenuityBoost Price TargetBuy$75.00 ➝ $85.00High
i
5/18/2020Stifel NicolausBoost Price TargetPositive ➝ Buy$70.00 ➝ $82.00High
i
5/8/2020CitigroupBoost Price TargetNeutral$53.00 ➝ $66.00Low
i
4/1/2020Robert W. BairdReiterated RatingBuy$75.00High
i
Rating by Michael Ulz at Robert W. Baird
2/18/2020Evercore ISIReiterated RatingBuyLow
i
2/16/2020JPMorgan Chase & Co.Reiterated RatingBuy$76.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
2/14/2020WedbushBoost Price TargetOutperform$71.00 ➝ $75.00High
i
2/14/2020CowenReiterated RatingBuy$75.00High
i
1/17/2020Morgan StanleyBoost Price TargetOverweight$73.00 ➝ $77.00Low
i
1/10/2020SunTrust BanksReiterated RatingBuy$75.00 ➝ $80.00High
i
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
12/18/2019Piper Jaffray CompaniesReiterated RatingBuy$70.00High
i
Rating by Christopher Raymond at Piper Jaffray Companies
12/18/2019CowenReiterated RatingBuy$59.00High
i
12/17/2019Morgan StanleyLower Price TargetOverweight$76.00 ➝ $73.00Medium
i
11/6/2019Morgan StanleyLower Price TargetOverweight$79.00 ➝ $76.00High
i
Rating by Jeffrey Hung at Morgan Stanley
11/6/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/5/2019CowenReiterated RatingBuy$62.00High
i
9/4/2019Piper Jaffray CompaniesSet Price TargetBuy$75.00Low
i
Rating by Christopher Raymond at Piper Jaffray Companies
9/4/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
9/4/2019SVB LeerinkReiterated RatingOutperform ➝ Positive$80.00 ➝ $85.00High
i
8/15/2019WedbushReiterated RatingBuy$75.00High
i
Rating by L. Chico at Wedbush
8/15/2019CowenReiterated RatingBuyHigh
i
8/5/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00Medium
i
8/4/2019BarclaysReiterated RatingBuy$87.00Medium
i
8/2/2019Morgan StanleyLower Price TargetOverweight$83.00 ➝ $79.00High
i
Rating by Jeffrey Hung at Morgan Stanley
8/2/2019WedbushReiterated RatingOutperform ➝ Outperform$75.00High
i
Rating by L. Chico at Wedbush
6/17/2019Morgan StanleySet Price TargetBuy$83.00Low
i
Rating by Jeffrey Hung at Morgan Stanley
5/9/2019BarclaysReiterated RatingBuyLow
i
5/7/2019WedbushReiterated RatingOutperform$88.00 ➝ $77.00High
i
3/27/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$68.00 ➝ $83.00Medium
i
Rating by Jeffrey Hung at Morgan Stanley
2/26/2019CowenReiterated RatingBuy$69.00High
i
2/22/2019Raymond JamesReiterated RatingOutperform ➝ Outperform$80.00Low
i
Rating by Laura Chico at Raymond James
2/21/2019CitigroupBoost Price TargetNeutral ➝ Neutral$54.00 ➝ $62.00High
i
2/20/2019Credit Suisse GroupReiterated RatingHold$59.00High
i
Rating by Martin Auster at Credit Suisse Group AG
1/23/2019SunTrust BanksBoost Price TargetBuy$71.00High
i
1/7/2019WedbushReiterated RatingOutperform$88.00Medium
i
1/7/2019CowenReiterated RatingBuyMedium
i
1/4/2019Credit Suisse GroupSet Price TargetHold$59.00Medium
i
Rating by Martin Auster at Credit Suisse Group AG
1/2/2019Raymond JamesDowngradeOutperform ➝ Market PerformMedium
i
Rating by Laura Chico at Raymond James
11/15/2018Credit Suisse GroupSet Price TargetHold$59.00High
i
Rating by Martin Auster at Credit Suisse Group AG
11/14/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/8/2018CitigroupUpgradeSell ➝ Neutral$46.00 ➝ $54.00N/A
i
11/7/2018Canaccord GenuityLower Price TargetBuy$90.00 ➝ $75.00Low
i
11/6/2018Raymond JamesBoost Price TargetOutperform ➝ Buy$53.00 ➝ $57.00Medium
i
Rating by Laura Chico at Raymond James
10/29/2018WedbushLower Price TargetOutperform ➝ Outperform$90.00 ➝ $88.00High
i
10/29/2018CitigroupLower Price TargetSell ➝ Sell$49.00 ➝ $46.00High
i
10/29/2018Morgan StanleySet Price TargetHold$92.00 ➝ $70.00High
i
Rating by Jeffrey Hung at Morgan Stanley
10/29/2018Credit Suisse GroupLower Price TargetNeutral ➝ Hold$78.00 ➝ $59.00High
i
Rating by Martin Auster at Credit Suisse Group AG
10/29/2018SunTrust BanksLower Price TargetBuy ➝ Buy$83.00 ➝ $54.00Medium
i
10/27/2018JPMorgan Chase & Co.Set Price TargetBuy$68.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/26/2018Raymond JamesSet Price TargetBuy$70.00Low
i
Rating by Laura Chico at Raymond James
10/26/2018Piper Jaffray CompaniesLower Price TargetOverweight$70.00High
i
10/7/2018JPMorgan Chase & Co.Reiterated RatingBuy$86.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
9/11/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$72.00 ➝ $94.00Low
i
9/10/2018Morgan StanleyReiterated RatingEqual ➝ Equal Weight$92.00Low
i
9/2/2018JMP SecuritiesReiterated RatingBuy$94.00Medium
i
8/30/2018WedbushBoost Price TargetOutperform ➝ Outperform$80.00 ➝ $90.00Medium
i
8/29/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/20/2018SunTrust BanksBoost Price TargetBuy ➝ Positive$83.00Low
i
8/6/2018WedbushBoost Price TargetOutperform ➝ Outperform$71.00 ➝ $80.00High
i
8/3/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$80.00 ➝ $90.00High
i
8/3/2018Robert W. BairdReiterated RatingBuy$95.00High
i
8/3/2018BarclaysReiterated RatingOverweight ➝ Overweight$74.00 ➝ $92.00High
i
8/3/2018Piper Jaffray CompaniesBoost Price TargetOverweight$85.00High
i
7/17/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$68.00 ➝ $95.00Low
i
6/21/2018Credit Suisse GroupDowngradeOutperform ➝ Neutral$67.00 ➝ $80.00High
i
5/11/2018BarclaysUpgradeEqual Weight ➝ Overweight$62.00 ➝ $74.00High
i
5/10/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$63.00Medium
i
4/18/2018CowenReiterated RatingBuyMedium
i
4/18/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$74.00 ➝ $77.00High
i
4/18/2018WedbushReiterated RatingOutperform ➝ Positive$64.00 ➝ $71.00High
i
4/18/2018JMP SecuritiesBoost Price TargetOutperform$70.00 ➝ $74.00High
i
4/18/2018SunTrust BanksUpgradeHold ➝ Buy$41.67 ➝ $55.00Low
i
4/17/2018Bank of AmericaBoost Price Target$61.00 ➝ $72.00Low
i
3/22/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$67.00Medium
i
2/23/2018Robert W. BairdReiterated RatingBuy$70.00Medium
i
2/21/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.00High
i
2/21/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$57.00 ➝ $60.00High
i
2/21/2018JPMorgan Chase & Co.Reiterated RatingMarket Outperform ➝ Overweight$68.00 ➝ $66.00High
i
2/21/2018Stifel NicolausReiterated RatingBuy ➝ Buy$85.00 ➝ $74.00High
i
1/22/2018Evercore ISIUpgradeIn-Line ➝ OutperformHigh
i
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$67.00Low
i
12/15/2017Raymond JamesReiterated RatingBuyLow
i
Rating by Laura Chico at Raymond James
12/5/2017Raymond JamesReiterated RatingBuyMedium
i
Rating by Laura Chico at Raymond James
12/5/2017Canaccord GenuitySet Price TargetBuy$80.00Medium
i
Rating by Arlinda Lee at Canaccord Genuity
12/5/2017BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $62.00High
i
12/4/2017Jefferies Financial GroupUpgradeHold ➝ Buy$58.00 ➝ $72.00High
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
11/16/2017Canaccord GenuitySet Price TargetBuy$83.00 ➝ $80.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
11/15/2017CowenReiterated RatingBuyN/A
i
11/5/2017JPMorgan Chase & Co.Reiterated RatingBuy$76.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/3/2017Robert W. BairdLower Price TargetOutperform$85.00 ➝ $80.00N/A
i
10/6/2017Morgan StanleyReiterated RatingEqual Weight$69.00 ➝ $71.00N/A
i
9/19/2017Robert W. BairdReiterated RatingBuyLow
i
9/14/2017WedbushUpgradeNeutral ➝ Outperform$62.00High
i
Rating by D. Nierengarten at Wedbush
9/12/2017Canaccord GenuityReiterated RatingBuyLow
i
Rating by Arlinda Lee at Canaccord Genuity
9/6/2017BarclaysInitiated CoverageEqual Weight$60.00High
i
8/23/2017Jefferies Financial GroupSet Price TargetHold$62.00Low
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
8/23/2017JPMorgan Chase & Co.Set Price TargetBuy$87.00 ➝ $76.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/23/2017JMP SecuritiesLower Price TargetMarket Outperform$90.00 ➝ $80.00Low
i
8/23/2017Morgan StanleyReiterated RatingEqual Weight$80.00 ➝ $69.00High
i
8/23/2017Stifel NicolausReiterated RatingBuy$95.00 ➝ $85.00High
i
8/23/2017SVB LeerinkReiterated RatingOutperform$89.00 ➝ $83.00High
i
8/23/2017CowenReiterated RatingOutperformHigh
i
8/23/2017SunTrust BanksDowngradeBuy ➝ Hold$105.00 ➝ $55.00High
i
8/22/2017Canaccord GenuityReiterated RatingBuy$98.00 ➝ $83.00High
i
Rating by Arlinda Lee at Canaccord Genuity
8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$63.00High
i
8/8/2017HC WainwrightReiterated RatingNeutral ➝ Neutral$72.00 ➝ $75.00Low
i
Rating by C. Werther at HC Wainwright
7/28/2017Canaccord GenuitySet Price TargetBuy$98.00Low
i
Rating by Arlinda Lee at Canaccord Genuity
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$72.00High
i
7/14/2017Jefferies Financial GroupReiterated RatingHold$68.00High
i
6/30/2017Stifel NicolausReiterated RatingBuy$111.00Low
i
6/29/2017CowenReiterated RatingOutperformLow
i
5/8/2017Canaccord GenuityReiterated RatingBuyLow
i
Rating by Arlinda Lee at Canaccord Genuity
5/8/2017Morgan StanleyLower Price TargetEqual Weight$84.00 ➝ $79.00Low
i
5/8/2017Jefferies Financial GroupBoost Price TargetHold$66.00 ➝ $68.00Low
i
Rating by Gena Wang at Jefferies Financial Group Inc.
4/19/2017Robert W. BairdReiterated RatingOutperform$90.00Medium
i
4/19/2017CowenReiterated RatingOutperformMedium
i
4/19/2017SunTrust BanksBoost Price TargetBuy$100.00 ➝ $105.00Medium
i
4/19/2017Canaccord GenuityReiterated RatingBuy$100.00High
i
Rating by Arlinda Lee at Canaccord Genuity
4/19/2017WedbushDowngradeOutperform ➝ Neutral$80.00 ➝ $75.00High
i
Rating by D. Nierengarten at Wedbush
4/19/2017HC WainwrightDowngradeBuy ➝ Neutral$88.00 ➝ $72.00High
i
Rating by C. Werther at HC Wainwright
4/6/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$109.00 ➝ $66.00High
i
Rating by Gena Wang at Jefferies Financial Group Inc.
3/23/2017HC WainwrightReiterated RatingBuyHigh
i
Rating by C. Werther at HC Wainwright
3/23/2017CowenReiterated RatingBuyHigh
i
3/23/2017Canaccord GenuityReiterated RatingBuy$100.00Medium
i
Rating by Arlinda Lee at Canaccord Genuity
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ NeutralHigh
i
Rating by Steven Breazzano at Piper Jaffray Companies
3/23/2017WedbushLower Price TargetBuy$88.00 ➝ $80.00High
i
Rating by D. Nierengarten at Wedbush
3/22/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$96.00 ➝ $70.00High
i
2/17/2017CowenReiterated RatingBuyN/A
i
2/17/2017WedbushInitiated CoverageOutperform$88.00N/A
i
2/17/2017Jefferies Financial GroupReiterated RatingBuy$109.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
11/30/2016CitigroupDowngradeNeutral ➝ SellN/A
i
Rating by Yigal Nochomovitz at Citigroup Inc.
11/30/2016WedbushReiterated RatingOutperform$92.00N/A
i
Rating by Heather Behanna at Wedbush
11/30/2016Piper Jaffray CompaniesReiterated RatingBuy$96.00N/A
i
Rating by steven breazzano at Piper Jaffray Companies
11/14/2016Jefferies Financial GroupSet Price TargetBuy$109.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
11/14/2016SVB LeerinkReiterated RatingOutperform$94.00 ➝ $90.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
11/14/2016CitigroupDowngradeNeutral ➝ Sell$66.00 ➝ $64.00N/A
i
11/11/2016Canaccord GenuitySet Price TargetBuy$103.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
11/9/2016JPMorgan Chase & Co.Reiterated RatingBuy$106.00N/A
i
Rating by cory kasimov at JPMorgan Chase & Co.
11/8/2016Piper Jaffray CompaniesReiterated RatingBuy$79.00N/A
i
Rating by steven breazzano at Piper Jaffray Companies
11/8/2016WedbushReiterated RatingOutperform$92.00N/A
i
Rating by Heather Behanna at Wedbush
10/21/2016Canaccord GenuitySet Price TargetBuy$120.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
9/25/2016HC WainwrightReiterated RatingBuy$102.00 ➝ $109.00N/A
i
9/20/2016Canaccord GenuitySet Price TargetBuy$120.00N/A
i
Rating by arlinda lee at Canaccord Genuity
9/20/2016SVB LeerinkReiterated RatingOutperform$85.00 ➝ $94.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
9/19/2016WedbushReiterated RatingOutperform$92.00N/A
i
Rating by Heather Behanna at Wedbush
9/18/2016Jefferies Financial GroupSet Price TargetBuy$109.00N/A
i
Rating by gena wang at Jefferies Financial Group Inc.
9/14/2016Credit Suisse GroupReiterated RatingBuy$101.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
9/12/2016Jefferies Financial GroupSet Price TargetBuy$109.00N/A
i
Rating by gena wang at Jefferies Financial Group Inc.
8/25/2016SVB LeerinkReiterated RatingBuy$86.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
8/9/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
8/9/2016Piper Jaffray CompaniesSet Price TargetBuy$70.00 ➝ $82.00N/A
i
Rating by steven breazzano at Piper Jaffray Companies
8/9/2016Credit Suisse GroupReiterated RatingBuy$101.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
8/9/2016WedbushReiterated RatingOutperform$92.00N/A
i
Rating by Heather Behanna at Wedbush
8/8/2016JPMorgan Chase & Co.Set Price TargetBuy$110.00N/A
i
Rating by cory kasimov at JPMorgan Chase & Co.
8/1/2016Jefferies Financial GroupSet Price TargetBuy$109.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
7/18/2016Robert W. BairdReiterated RatingOutperform$85.00N/A
i
7/17/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
7/17/2016Piper Jaffray CompaniesReiterated RatingOverweight$70.00N/A
i
7/15/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
7/15/2016SVB LeerinkReiterated RatingBuy$85.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
7/15/2016Canaccord GenuityReiterated RatingBuy$120.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
7/12/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
7/7/2016Piper Jaffray CompaniesInitiated CoverageOverweight$70.00N/A
i
6/28/2016WedbushReiterated RatingOutperform$92.00N/A
i
Rating by Heather Behanna at Wedbush
6/28/2016Bank of AmericaInitiated CoverageBuy$72.00N/A
i
6/16/2016Canaccord GenuityReiterated RatingBuy$120.00N/A
i
Rating by Arlinda Lee at Canaccord Genuity
6/16/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
6/10/2016SVB LeerinkReiterated RatingOutperform$80.00 ➝ $85.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
6/8/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by Matthew Harrison at Morgan Stanley
6/8/2016JMP SecuritiesReiterated RatingBuy$80.00 ➝ $84.00N/A
i
6/8/2016Jefferies Financial GroupReiterated RatingBuy$109.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
5/25/2016Credit Suisse GroupReiterated RatingBuy$101.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/10/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/10/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Arlinda Lee at Canaccord Genuity
5/10/2016SVB LeerinkReiterated RatingBuy$80.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
5/10/2016Jefferies Financial GroupReiterated RatingBuy$109.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
5/10/2016WedbushReiterated RatingOutperform$99.00 ➝ $92.00N/A
i
4/4/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Arlinda Lee at Canaccord Genuity
3/7/2016Robert W. BairdInitiated CoverageOutperform$85.00N/A
i
(Data available from 3/5/2016 forward)
Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Read More

Today's Range

Now: $117.02
$110.78
$119.16

50 Day Range

MA: $145.21
$125.30
$167.73

52 Week Range

Now: $117.02
$31.99
$179.65

Volume

29,360 shs

Average Volume

466,050 shs

Market Capitalization

$7.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Ultragenyx Pharmaceutical?

The following equities research analysts have issued reports on Ultragenyx Pharmaceutical in the last twelve months: Bank of America Co., Barclays PLC, Canaccord Genuity, Citigroup Inc., Credit Suisse Group AG, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Robert W. Baird, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, TheStreet, Truist, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for RARE.

What is the current price target for Ultragenyx Pharmaceutical?

15 Wall Street analysts have set twelve-month price targets for Ultragenyx Pharmaceutical in the last year. Their average twelve-month price target is $131.20, suggesting a possible upside of 10.6%. Barclays PLC has the highest price target set, predicting RARE will reach $186.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $66.00 for Ultragenyx Pharmaceutical in the next year.
View the latest price targets for RARE.

What is the current consensus analyst rating for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical currently has 6 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RARE will outperform the market and that investors should add to their positions of Ultragenyx Pharmaceutical.
View the latest ratings for RARE.

What other companies compete with Ultragenyx Pharmaceutical?

How do I contact Ultragenyx Pharmaceutical's investor relations team?

Ultragenyx Pharmaceutical's physical mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company's listed phone number is 415-483-8800 and its investor relations email address is [email protected] The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.